|
|
||||||||
633 Salk Hall, Center for Pharmacogenetics School of Pharmacy University of Pittsburgh Pittsburgh, Pa 15213
Correspondence: Address correspondence to LH. E-mail Huangl{at}msx.upmc.edu; fax 412-648-1664.

The systemic delivery of naked DNA to within diseased organs offers both advantages and challenges for gene therapy. The diaphragm tissue shown above comes from mutant (mdx) mice that are deficient in dystrophin. Subsequent to receiving therapeutic DNA via intravascular injection, however, the mice express dystrophin (immunostained red) beneath cell membranes.
Skeletal muscle is a promising target tissue for the gene therapy of both muscle and non-muscle disorders. Gene transfer into muscle tissue can produce a variety of physiologically active proteins and may ultimately be applied to the treatment of many diseases. A variety of methods have been studied to transfer genes into skeletal muscle, including viral and non-viral vectors. In this review, we discuss recent developments in the non-viral delivery of genes to muscles.
This article has been cited by other articles:
![]() |
D. Shiokawa, T. Matsushita, Y. Shika, M. Shimizu, M. Maeda, and S.-i. Tanuma DNase X Is a Glycosylphosphatidylinositol-anchored Membrane Enzyme That Provides a Barrier to Endocytosis-mediated Transfer of a Foreign Gene J. Biol. Chem., June 8, 2007; 282(23): 17132 - 17140. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ASPET Journals | Pharmacological Reviews | Drug Metabolism and Disposition |
| Molecular Interventions | Molecular Pharmacology | J Pharmacology and Exp Therapeutics |